Buy Like Buffett
Watchlist

Flagship explainer

How Amylyx Pharmaceuticals, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$0 · UnavailableCost of revenue$0 · UnavailableGross profit$0 · UnavailableOperating income−$153M · UnavailableIncome before tax−$145M · UnavailableIncome tax$46000 · UnavailableNet income−$145M · UnavailableAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$0Unavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
Cost of revenue$0Unavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
$0Unavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
−$153MUnavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
Income before tax−$145MUnavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
Income tax$46000Unavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
−$145MUnavailable
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-086645 · filed Mar 3, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full Amylyx Pharmaceuticals, Inc. analysis at Buy Like Buffett